Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
64 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Pipeline Review, H2 2016', provides in depth analysis on Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted pipeline therapeutics. The report provides comprehensive information on the Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - The report reviews Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics and enlists all their major and minor projects - The report assesses Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) Overview 7 Therapeutics Development 8 Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Products under Development by Stage of Development 8 Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Products under Development by Therapy Area 9 Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Products under Development by Indication 10 Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Products under Development by Companies 14 Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Therapeutics Assessment 17 Assessment by Monotherapy/Combination Products 17 Assessment by Mechanism of Action 18 Assessment by Route of Administration 19 Assessment by Molecule Type 21 Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Companies Involved in Therapeutics Development 23 FibroGen, Inc. 23 ProMetic Life Sciences Inc. 24 RXi Pharmaceuticals Corporation 25 Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Drug Profiles 26 Antisense RNAi Oligonucleotide to Inhibit CTGF for PVR - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 OLX-101 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 OLX-201 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 pamrevlumab - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 PBI-4050 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 RXI-109 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 RXI-209 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Dormant Projects 48 Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Discontinued Products 49 Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Featured News & Press Releases 50 Jun 09, 2016: ProMetic to present new data on how PBI-4050 keeps pancreatic beta cells alive at the American Diabetic Associations upcoming annual meeting 50 May 18, 2016: Health Canada authorizes ProMetic to proceed with its PBI-4050 clinical trial in patients with cystic fibrosis 51 Apr 28, 2016: RXi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise with Successful Topical Delivery of sd-rxRNA to the Cornea in an in vivo Corneal Wound Model 51 Apr 26, 2016: ProMetic PBI-4050: efficacy further evidenced in type 2 diabetic and metabolic syndrome clinical trial 52 Apr 25, 2016: RXi Pharmaceuticals to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference 53 Apr 19, 2016: RXi Pharmaceuticals Fortifies its Novel RNAi Patent Portfolio with Notice of Allowance for Lead Clinical Candidate RXI-109 54 Apr 14, 2016: ProMetic confirms PBI-4050 Anti-Fibrotic Effect in Nash Model and on Human Hepatic Stellate Cells 55 Mar 31, 2016: Rxi Pharmaceuticals Strengthens Intellectual Property Portfolio for Dermal Indications 55 Mar 28, 2016: RXi Pharmaceuticals to Present at the Oligonucleotide Therapeutics and Delivery Conference 56 Mar 22, 2016: ProMetic confirms PBI-4050 positive effects on novel biomarkers in patients suffering from metabolic syndrome and Type 2 diabetes 57 Mar 15, 2016: ProMetic announces the addition of scleroderma to PBI-4050 targeted indications 57 Mar 11, 2016: FibroGen Announces Publication of Phase 2 Study Results Supporting the Potential of FG-3019 to Treat Patients With Idiopathic Pulmonary Fibrosis 58 Jan 27, 2016: FibroGen Announces Early Phase 2 Data From a Clinical Study of FG-3019 in Combination With Chemotherapy as Neoadjuvant in Locally Advanced, Unresectable Pancreatic Cancer 59 Jan 06, 2016: FibroGen Enrolls First Patients in Phase 2 Clinical Study of Anti-Fibrotic Drug Candidate FG-3019 for the Treatment of Duchenne Muscular 60 Dec 14, 2015: Prometic's PBI-4050 To Target Cystic Fibrosis As Its Next Orphan Indication 62 Appendix 63 Methodology 63 Coverage 63 Secondary Research 63 Primary Research 63 Expert Panel Validation 63 Contact Us 63 Disclaimer 64
List of Tables
Number of Products under Development for, H2 2016 8 Number of Products under Development by Therapy Area, H2 2016 9 Number of Products under Development by Indication, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Early Stage Products, H2 2016 13 Number of Products under Development by Companies, H2 2016 14 Products under Development by Companies, H2 2016 15 Products under Development by Companies, H2 2016 (Contd..1) 16 Assessment by Monotherapy/Combination Products, H2 2016 17 Number of Products by Stage and Mechanism of Action, H2 2016 18 Number of Products by Stage and Route of Administration, H2 2016 20 Number of Products by Stage and Molecule Type, H2 2016 22 Pipeline by FibroGen, Inc., H2 2016 23 Pipeline by ProMetic Life Sciences Inc., H2 2016 24 Pipeline by RXi Pharmaceuticals Corporation, H2 2016 25 Dormant Projects, H2 2016 48 Discontinued Products, H2 2016 49
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
